 The FDA has signed off Biomea Fusion Incs NASDAQ: BMEA Investigational New Drug application to begin a Phase 1 trial of BMF-219, a selective irreversible menin inhibitor. The trial will include adult patients with relapsed or refractory acute leukemia, including those with an MLLKM2TA gene rearrangement or NPM1 mutation. 